We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-17.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.52B
AUM Growth
-$55.5M
Cap. Flow
+$168M
Cap. Flow %
11.04%
Top 10 Hldgs %
38.58%
Holding
149
New
11
Increased
70
Reduced
43
Closed
11

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$41.6M
2
ILMN icon
Illumina
ILMN
+$33.2M
3
TDOC icon
Teladoc Health
TDOC
+$29.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$25.9M
5
ABT icon
Abbott
ABT
+$14.7M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$17.1M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$15.1M
3
EW icon
Edwards Lifesciences
EW
+$14.5M
4
PACB icon
Pacific Biosciences
PACB
+$13.9M
5
LH icon
Labcorp
LH
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.15%
2 Industrials 0.99%
3 Technology 0.52%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OXFD
76
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.92M 0.26%
306,606
+84,769
+38% +$1.29M
BMRN icon
77
BioMarin Pharmaceuticals
BMRN
$11.5B
$3.91M 0.26%
45,969
-1,900
-4% -$181K
INSP icon
78
Inspire Medical Systems
INSP
$1.46B
$3.91M 0.26%
92,616
+1,920
+2% +$81.6K
TNDM icon
79
Tandem Diabetes Care
TNDM
$1.17B
$3.77M 0.25%
99,253
+2,058
+2% +$72.7K
INCY icon
80
Incyte
INCY
$23.4B
$3.73M 0.25%
58,650
+6,300
+12% +$409K
HOLX
81
DELISTED
Hologic
HOLX
$3.7M 0.24%
90,000
-271,894
-75% -$11.2M
VEEV icon
82
Veeva Systems
VEEV
$31.7B
$3.4M 0.22%
38,092
+5,401
+17% +$493K
MDSO
83
DELISTED
Medidata Solutions, Inc.
MDSO
$3.32M 0.22%
49,211
+12,304
+33% +$868K
HZNP
84
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.29M 0.22%
168,500
-53,178
-24% -$1.04M
CHRS icon
85
Coherus Oncology
CHRS
$216M
$3.25M 0.21%
358,935
+143,000
+66% +$1.65M
LGND icon
86
Ligand Pharmaceuticals
LGND
$6.08B
$3.24M 0.21%
38,264
+20,198
+112% +$2.15M
STIM icon
87
Neuronetics
STIM
$113M
$3.2M 0.21%
165,400
+53,493
+48% +$1.17M
NVRO
88
DELISTED
NEVRO CORP.
NVRO
$3.17M 0.21%
81,438
+1,023
+1% +$45.5K
CERN
89
DELISTED
Cerner Corp
CERN
$3.1M 0.2%
59,146
– –
AMED
90
DELISTED
Amedisys
AMED
$2.95M 0.19%
25,204
– –
PEN icon
91
Penumbra
PEN
$12.5B
$2.94M 0.19%
24,050
+4,908
+26% +$657K
NBIX icon
92
Neurocrine Biosciences
NBIX
$17.2B
$2.86M 0.19%
40,050
-1,500
-4% -$144K
JNJ icon
93
Johnson & Johnson
JNJ
$609B
$2.58M 0.17%
20,000
– –
MASI
94
DELISTED
Masimo
MASI
$2.45M 0.16%
22,780
+3,304
+17% +$368K
ICPT
95
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.33M 0.15%
23,148
-1,000
-4% -$104K
CSLT
96
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.3M 0.15%
1,059,515
+170,673
+19% +$423K
AGN
97
DELISTED
Allergan plc
AGN
$2.14M 0.14%
16,000
+3,000
+23% +$492K
SGEN
98
DELISTED
Seagen Inc. Common Stock
SGEN
$1.98M 0.13%
35,000
-11,950
-25% -$750K
EXEL icon
99
Exelixis
EXEL
$14.1B
$1.85M 0.12%
+94,000
New +$1.68M
CVS icon
100
CVS Health
CVS
$137B
$1.69M 0.11%
25,825
+17,825
+223% +$1.33M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2018 Portfolio in Review

As of Q4 2018, Bellevue Group held 149 positions worth $1.52B, down 3.5% from $1.58B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group deployed $168M of net new capital in Q4 2018, opening 11 new positions and adding to 70 existing holdings. Its largest new stake was QuidelOrtho: 125,000 shares worth $6.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 93% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Centene, an estimated $17.1M trimmed.

  • Bellevue Group's largest Q4 2018 buy was QuidelOrtho: 125,000 shares worth $6.1M.
  • Bellevue Group added most to Align Technology in Q4 2018, an estimated $41.6M increase.
  • Bellevue Group's biggest Q4 2018 reduction was Centene, cutting an estimated $17.1M.
  • Bellevue Group fully exited K2M Group Holdings, Inc in Q4 2018, selling an estimated $15.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $1.52B portfolio in Q4 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q4 2018.
  • Bellevue Group's portfolio value fell 3.5% quarter-over-quarter to $1.52B.

Based on Bellevue Group's 13F filing for Q4 2018, filed 12 Feb 2019.